At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 233 enrolled
Drug / intervention
IBI308 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating IBI308, IBI308\Cisplatinum\Pemetrexed, and 4 other interventions for Cancer, Solid Tumor. Completed, enrolled 233 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and immunogenicity of IBI308.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartOct 2016
Primary CompletionSep 2020
TodayJul 2026
First PostedOct 18, 2016
Enrollment StartOct 19, 2016
Primary CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.7 years ago
Interventions
IBI308drug
IBI308\Cisplatinum\Pemetrexeddrug
IBI308\cisplatin\gemcitabinedrug
IBI308\oxaliplatin\capecitabinedrug
IBI308\etoposide\cisplatindrug
IBI308\irinotecan\5-FUdrug